Sanofi stops breast cancer drug Amcenestrant Clinical Development Program

Published On 2022-08-19 13:00 GMT | Update On 2022-08-19 13:00 GMT

Pharma major, Sanofi, has announced the discontinuation of the global clinical development program of amcenestrant, an investigational oral selective estrogen receptor degrader (SERD).

The decision is based on the outcome of a prespecified interim analysis of the Phase 3 AMEERA-5 trial evaluating amcenestrant in combination with palbociclib compared with letrozole in combination with palbociclib in patients with estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer.

For more details click on the link given below :

Sanofi Halts Breast Cancer Drug Amcenestrant Clinical Development Program

Full View

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Roshni Dhar

Roshni Dhar, a Mass com graduate with a soft corner for health happenings, joined Medical Dialogues as a news anchor in 2021. Inspired by her mother who is a gynaecologist, she likes to keep herself and the world updated on the occurring in the medical field. She covers various aspects of health news for MDTV at Medical Dialogues. She can be contacted at editorial@medicaldialogues.in. Contact no. 011-43720751

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Sanofi stops breast cancer drug Amcenestrant Clinical Development Program

Similar News